Starpharma's VivaGel® condom receives approval in Japan

Company News

by Rachael Jones

Biotech company Starpharma (ASX:SPL) has today announced that the VivaGel® condom has received final regulatory approval and is now able to be marketed in Japan.

Starpharma has worked closely with its commercial partner for Japan, Okamoto Industries throughout the regulatory process.

Okamoto has already commenced key launch preparations, including labelling and manufacturing activities, and plans to launch the VivaGel® condom in the first half of 2019.

Okamoto is Japan’s leading marketer of condoms with a majority share of the Japanese condom market, which is one of the world’s largest condom markets and estimated to be in the order of US$500 million per annum.

Shares in Starpharma (ASX:SPL) trading 5.5 per cent lower at $1.12
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.